These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19064724)

  • 1. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.
    Bruno B; Rotta M; Patriarca F; Mattei D; Allione B; Carnevale-Schianca F; Sorasio R; Rambaldi A; Casini M; Parma M; Bavaro P; Onida F; Busca A; Castagna L; Benedetti E; Iori AP; Giaccone L; Palumbo A; Corradini P; Fanin R; Maloney D; Storb R; Baldi I; Ricardi U; Boccadoro M
    Blood; 2009 Apr; 113(14):3375-82. PubMed ID: 19064724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of allografting with autografting for newly diagnosed myeloma.
    Bruno B; Rotta M; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Sorasio R; Omedè P; Baldi I; Bringhen S; Massaia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Storb R; Ciccone G; Boccadoro M
    N Engl J Med; 2007 Mar; 356(11):1110-20. PubMed ID: 17360989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.
    Giaccone L; Storer B; Patriarca F; Rotta M; Sorasio R; Allione B; Carnevale-Schianca F; Festuccia M; Brunello L; Omedè P; Bringhen S; Aglietta M; Levis A; Mordini N; Gallamini A; Fanin R; Massaia M; Palumbo A; Ciccone G; Storb R; Gooley TA; Boccadoro M; Bruno B
    Blood; 2011 Jun; 117(24):6721-7. PubMed ID: 21490341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
    Rotta M; Storer BE; Sahebi F; Shizuru JA; Bruno B; Lange T; Agura ED; McSweeney PA; Pulsipher MA; Hari P; Maziarz RT; Chauncey TR; Appelbaum FR; Sorror ML; Bensinger W; Sandmaier BM; Storb RF; Maloney DG
    Blood; 2009 Apr; 113(14):3383-91. PubMed ID: 19015394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.
    Passera R; Pollichieni S; Brunello L; Patriarca F; Bonifazi F; Montefusco V; Falda M; Montanari M; Guidi S; Giaccone L; Mordini N; Carella AM; Bavaro P; Milone G; Benedetti F; Ciceri F; Scimè R; Benedetti E; Castagna L; Festuccia M; Rambaldi A; Bacigalupo A; Corradini P; Bosi A; Boccadoro M; Bandini G; Fanin R; Bruno B
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):940-8. PubMed ID: 23538113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
    Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
    Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
    Kröger N; Sayer HG; Schwerdtfeger R; Kiehl M; Nagler A; Renges H; Zabelina T; Fehse B; Ayuk F; Wittkowsky G; Schmitz N; Zander AR
    Blood; 2002 Dec; 100(12):3919-24. PubMed ID: 12393448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
    Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
    Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
    Vesole DH; Zhang L; Flomenberg N; Greipp PR; Lazarus HM; Huff CA;
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):83-91. PubMed ID: 19135946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
    Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
    Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
    Lee CK; Badros A; Barlogie B; Morris C; Zangari M; Fassas A; van Rhee F; Cottler-Fox M; Jacobson J; Thertulien R; Muwalla F; Mazher S; Anaissie E; Tricot G
    Exp Hematol; 2003 Jan; 31(1):73-80. PubMed ID: 12543109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
    Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
    J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.